{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T08:50:36Z","timestamp":1747212636269,"version":"3.40.5"},"reference-count":75,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"4","license":[{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Alerg Mex"],"abstract":"<jats:p>With the advent of the description of autoimmune encephalitis by different neuronal cell-surface antibodies (anti-NMDAr, among others) and that psychosis may be the only manifestation without neurological symptoms (epilepsy, movement disorders, autonomic dysfunction, altered state of consciousness) in 6.5 % of patients, the term \u201cautoimmune psychosis\u201d has become remarkably interesting among researchers. In 2020, an international consensus for the description and diagnostic approach of autoimmune psychosis was created. Through this consensus, by taking different criteria into account, the definition of autoimmune psychosis was proposed at different degrees of certainty (possible, probable, and defined). The purpose of these criteria is to underpin the autoimmune origin in patients who present psychosis with atypical characteristics, thus justifying the realization of laboratory studies and complementary clinical tests (lumbar puncture, electroencephalogram, and magnetic resonance imaging of the brain); in addition, these criteria are applied in patients with psychosis without neurological symptoms that do not fully meet the criteria of autoimmune encephalitis. As in autoimmune encephalitis, the early initiation of immunotherapy has a direct impact on the functional prognosis of patients, so an early initiation of treatment must be considered in clinical scenarios of probable or definite autoimmune psychosis.<\/jats:p>","DOI":"10.29262\/ram.v68i4.981","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T21:08:09Z","timestamp":1638911289000},"page":"276-290","source":"Crossref","is-referenced-by-count":2,"title":["Psicosis autoinmune","Autoimmune psychosis"],"prefix":"10.29262","volume":"68","author":[{"given":"Miguel","family":"Restrepo-Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"L\u00f3pez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Espinola-Nadurille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo","family":"Bayliss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ra\u00fal","family":"Medina-Rioja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Mart\u00ednez-\u00c1ngeles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Galnares-Olalde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Alberto","family":"T\u00e9llez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Ram\u00edrez-Berm\u00fadez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11808","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Pape K, Tamouza R, Leboyer M, Zipp F. Immunoneuropsychiatry - novel perspectives on brain disorders. Nat Rev Neurol. 2019;15(6):317-328. DOI: 10.1038\/s41582-019-0174-4","DOI":"10.1038\/s41582-019-0174-4"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Al-Diwani AAJ, Pollak TA, Irani SR, Lennox BR. Psychosis: an autoimmune disease? Immunology. 2017;152(3):388-401. DOI: 10.1111\/imm.12795.","DOI":"10.1111\/imm.12795"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Ellul P, Groc L, Tamouza R, Leboyer M. The clinical challenge of autoimmune psychosis: learning from Anti-NMDA receptor autoantibodies. Front Psychiatry. 2017;8:1-6. DOI: 10.3389\/fpsyt.2017.00054","DOI":"10.3389\/fpsyt.2017.00054"},{"key":"ref3","unstructured":"Pollak TA, Lennox B, Vincent A, M\u00fcller S, Benros ME, Pr\u00fcss H, et al. An international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin: the concept of autoimmune psychosis. Lancet Psychiatry. 2019;30290-30291."},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Maat P, de Graaff E, van Beveren NM, Hulsenboom E, Verdijk RM, Koorengevel K, et al. Psychiatric phenomena as initial manifestation of encephalitis by anti-NMDAR antibodies. Acta Neuropsychiatr. 2013;25(3):128-136. DOI: 10.1111\/acn.12013","DOI":"10.1111\/acn.12013"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Maneta E, Garc\u00eda G. Psychiatric manifestations of anti-NMDA receptor encephalitis : neurobiological underpinnings and differential diagnostic implications. Psychosomatics. 2014;55(1):1-8. DOI: 10.1016\/j.psym.2013.06.002","DOI":"10.1016\/j.psym.2013.06.002"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Herken J, Pr\u00fcss H. Red flags: Clinical signs for identifying autoimmune encephalitis in psychiatric patients. Front Psychiatry. 2017;8:25. DOI: 10.3389\/fpsyt.2017.00025","DOI":"10.3389\/fpsyt.2017.00025"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Zandi MS, Irani SR, Lang B, Waters P, Jones PB, McKenna P, et al. Disease-relevant autoantibodies in first episode schizophrenia. J Neurol. 2011;258(4):686-688. DOI: 10.1007\/s00415-010-5788-9","DOI":"10.1007\/s00415-010-5788-9"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Titulaer MJ, McCracken L, Gabilondo I, Armangu\u00e9 T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157-165. DOI: 10.1016\/S1474-4422(12)70310-1","DOI":"10.1016\/S1474-4422(12)70310-1"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Diagnostic and Statistical Manual of Mental Disorders (DSM-5). EE. UU.: American Psychiatric Association; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref10","unstructured":"Ram\u00edrez-Berm\u00fadez J, Sosa-Ortiz A. Principios de neuropsiquiatr\u00eda. Abordaje de los s\u00edndromes neuropsiqui\u00e1tricos. M\u00e9xico: Asociaci\u00f3n Psiqui\u00e1trica Mexicana; 2018."},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"How OS. Psychotic disorders. A Prim Child Adolesc Psychiatry. 2008;193-214.","DOI":"10.1142\/9789812779939_0017"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Klein MO, Battagello DS, Cardoso AR, Hauser DN, Bittencourt JC, et al. Dopamine: functions, signaling, and association with neurological diseases. Cell Mol Neurobiol. 2019;39(1):31-59. DOI: 10.1007\/s10571-018-0632-3","DOI":"10.1007\/s10571-018-0632-3"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Kapur S. Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003;160(1):13-23. DOI: 10.1176\/appi.ajp.160.1.13","DOI":"10.1176\/appi.ajp.160.1.13"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Ram\u00edrez-Berm\u00fadez J, Ruiz-Chow A, P\u00e9rez-Neri I, Soto-Hern\u00e1ndez JL, Flores-Hern\u00e1ndez R, Nente F, et al. Cerebrospinal fluid homovanillic acid is correlated to psychotic features in neurological patients with delirium. Gen Hosp Psychiatry. 2008;30(4):337-343. DOI: 10.1016\/j.genhosppsych.2008.01.007","DOI":"10.1016\/j.genhosppsych.2008.01.007"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Ram\u00edrez-Berm\u00fadez J, P\u00e9rez-Neri I, Montes S, Nente F, Ram\u00edrez-Abascal M, Carrillo-Mezo R, et al. Dopaminergic hyperactivity in neurological patients with delirium. Arch Med Res. 2019;50(8):477-483. DOI: 10.1016\/j.arcmed.2019.11.002","DOI":"10.1016\/j.arcmed.2019.11.002"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020;19(1):15-33. DOI: 10.1002\/wps.20693","DOI":"10.1002\/wps.20693"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Stahl SM. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: Dopamine, serotonin, and glutamate. CNS Spectr. 2018;23(3):187-191. DOI: 10.1017\/S1092852918001013","DOI":"10.1017\/S1092852918001013"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Selvaraj S, Arnone D, Cappai A, Howes O. Alterations in the serotonin system in schizophrenia: A systematic review and meta-analysis of postmortem and molecular imaging studies. Neurosci Biobehav Rev. 2014;45:233-245. DOI: 10.1016\/j.neubiorev.2014.06.005","DOI":"10.1016\/j.neubiorev.2014.06.005"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Brown AS, Schaefer CA, Quesenberry CP, Liu L, Babulas VP, Susser ES. Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am J Psychiatry. 2005;162(4):767-773. DOI: 10.1176\/appi.ajp.d162.4.767","DOI":"10.1176\/appi.ajp.162.4.767"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Takei N, Van Os J, Murray RM. Maternal exposure to influenza and risk of schizophrenia: a 22 year study from The Netherlands. J Psychiatr Res. 1995;29(6):435-445. DOI: 10.1016\/0022-3956(95)00031-3","DOI":"10.1016\/0022-3956(95)00031-3"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Pedersen MS, Benros ME, Agerbo E, B\u00f8rglum AD, Mortensen PB. Schizophrenia in patients with atopic disorders with particular emphasis on asthma: a Danish population-based study. Schizophr Res. 2012;138(1):58-62. DOI: 10.1016\/j.schres.2012.02.019","DOI":"10.1016\/j.schres.2012.02.019"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Benros ME, Eaton WW, Mortensen PB. The epidemiologic evidence linking autoimmune diseases and psychosis. Biol Psychiatry. 2014;75(4):300-306. DOI: 10.1016\/j.biopsych.2013.09.023","DOI":"10.1016\/j.biopsych.2013.09.023"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB. Autoimmune diseases and severe infections as risk factors for schizophrenia: A 30-year population-based register study. Am J Psychiatry. 2011;168(12):1303-1310. DOI: 10.1176\/appi.ajp.2011.11030516","DOI":"10.1176\/appi.ajp.2011.11030516"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Man\u00e9-Damas M, Hoffmann C, Zong S, Tan A, Molenaar PC, et al. Autoimmunity in psychotic disorders. Where we stand, challenges and opportunities. Autoimmun Rev. 2019;18(9):102348. DOI: 10.1016\/j.autrev.2019.102348","DOI":"10.1016\/j.autrev.2019.102348"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol. 2005;58(4):594-604. DOI: 10.1002\/ana.20614","DOI":"10.1002\/ana.20614"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Dalmau J, T\u00fcz\u00fcn E, Wu H, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25-36. DOI: 10.1002\/ana.21050","DOI":"10.1002\/ana.21050"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Pollak TA, Lennox BR, M\u00fcller S, Benros ME, Pr\u00fcss H, van Elst LT, et al. Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry. 2020;7(1):93-108. DOI: 10.1016\/S2215-0366(19)30290-1","DOI":"10.1016\/S2215-0366(19)30290-1"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Kirkbride JB, Errazuriz A, Croudace TJ, Morgan C, Jackson D, Boydell J, et al. Incidence of schizophrenia and other psychoses in England, 1950-2009: a systematic review and meta-analyses. PLoS One. 2012;7(3):e31660. DOI: 10.1371\/journal.pone.0031660","DOI":"10.1371\/journal.pone.0031660"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Jongsma HE, Turner C, Kirkbride JB, Jones PB. International incidence of psychotic disorders, 2002-17: a systematic review and meta-analysis. Lancet Public Health. 2019;4(5):e229-e244. DOI: 10.1016\/S2468-2667(19)30056-8","DOI":"10.1016\/S2468-2667(19)30056-8"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun. 2009;33(3-4):197-207. DOI: 10.1016\/j.jaut.2009.09.008","DOI":"10.1016\/j.jaut.2009.09.008"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Cullen AE, Holmes S, Pollak TA, Blackman G, Joyce DW, Kempton MJ, et al. Associations between non-neurological autoimmune disorders and psychosis: a meta-analysis. Biol Psychiatry. 2019;85(1):35-48. DOI: 10.1016\/j.biopsych.2018.06.016","DOI":"10.1016\/j.biopsych.2018.06.016"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Jeltsch-David H, Muller S. Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers. Nat Rev Neurol. 2014;10(10):579-596. DOI: 10.1038\/nrneurol.2014.148","DOI":"10.1038\/nrneurol.2014.148"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Fragoso-Loyo H, Cabiedes J, Orozco-Narv\u00e1ez A, D\u00e1vila-Maldonado L, Atisha-Fregoso Y, Diamond B, et al. Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis. PLoS One. 2008;3(10):e3347. DOI: 10.1371\/journal.pone.0003347","DOI":"10.1371\/journal.pone.0003347"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Zhou JY, Xu B, Lopes J, et al. Hashimoto encephalopathy: literature review. Acta Neurol Scand. 2017;135(3):285-290. DOI: 10.1111\/ane.12618","DOI":"10.1111\/ane.12618"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis. 2012;54(7):899-904. DOI: 10.1093\/cid\/cir1038","DOI":"10.1093\/cid\/cir1038"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Zhang L, Wu M-Q, Hao ZL, Vance-Chiang SM, Shuang K, Lin M-T, et al. Clinical characteristics, treatments, and outcomes of patients with anti-N-methyl-D-aspartate receptor encephalitis: a systematic review of reported cases. Epilepsy Behav. 2017;68:57-65. DOI: 10.1016\/j.yebeh.2016.12.019","DOI":"10.1016\/j.yebeh.2016.12.019"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Steiner J, Walter M, Glanz W, Sarnyai Z, Bernstein H-G, Vielhaber S, et al. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: Specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry. 2013;70(3):271-278. DOI: 10.1001\/2013.jamapsychiatry.86","DOI":"10.1001\/2013.jamapsychiatry.86"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"van Sonderen A, Schreurs MW, Wirtz PW, Sillevis-Smitt PAE, Titulaer MJ. From VGKC to LGI1 and Caspr2 encephalitis: the evolution of a disease entity over time. Autoimmun Rev. 2016;15(10):970-974. DOI: 10.1016\/j.autrev.2016.07.018","DOI":"10.1016\/j.autrev.2016.07.018"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Oviedo-Salcedo T, de Witte L, K\u00fcmpfel T, Kahn RS, Falkai P, Eichhorn P, et al. Absence of cerebrospinal fluid antineuronal antibodies in schizophrenia spectrum disorders. Br J Psychiatry. 2018;212(5):318-320. DOI: 10.1192\/bjp.2018.24","DOI":"10.1192\/bjp.2018.24"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Dalmau J, Armangu\u00e9 T, Planagum\u00e0 J, Radosevic M, Mannara F, Leypoldt F, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019;18(11):1045-1057. DOI: 10.1016\/S1474-4422(19)30244-3","DOI":"10.1016\/S1474-4422(19)30244-3"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"van Sonderen A, Thijs RD, Coenders EC, Jiskoot LC, S\u00e1nchez E, de Brujin MAAM, et al. Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up. Neurology. 2016;87(14):1449-1456. DOI: 10.1212\/WNL.0000000000003173","DOI":"10.1212\/WNL.0000000000003173"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Vogrig A, Mu\u00f1iz-Castillo M, Desestret V,Joubert B, Honnorat J. Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections,and checkpoint inhibitors. Ther Adv Neurol Disord. 2020;13:1756286420932797. DOI: 10.1177\/1756286420932797","DOI":"10.1177\/1756286420932797"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Patterson KR, Dalmau J, Lancaster E. Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia. Ann Neurol. 2018;83(1):40-51. DOI: 10.1002\/ana.25120","DOI":"10.1002\/ana.25120"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Jia Y, Li M, Wang H, Zhang M, Wang Y. The peculiar clinical symptoms and treatment of limbic encephalitis associated with AMPA receptor antibody. Eur Neurol. 2021;84(3):206-211. DOI: 10.1159\/000515592","DOI":"10.1159\/000515592"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"H\u00f6ftberger R, van Sonderen A, Leypoldt F,Houghton D, Geschwind M, Gelfand J, et al. Encephalitis and AMPA receptor antibodies. Neurology. 2015;84(24)2403-2412. DOI: 10.1212\/WNL.0000000000001682","DOI":"10.1212\/WNL.0000000000001682"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Guo CY, Gelfand JM, Geschwind MD. Anti-gamma-aminobutyric acid receptor type A encephalitis: a review. Curr Opin Neurol. 2020;33(3):372-380. DOI: 10.1097\/WCO.0000000000000814","DOI":"10.1097\/WCO.0000000000000814"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Zhu F, Shan W, Lv R, Li Z, Wang Q. Clinical characteristics of anti-GABA-B receptor encephalitis. Front Neurol. 2020;11:403. DOI: 10.3389\/fneur.2020.00403","DOI":"10.3389\/fneur.2020.00403"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Dubey D, Lennon VA, Gadoth A, Pittock SJ, Flanagan EP, Schmeling JE, et al. Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology. 2018;90(2):e103-e110. DOI: 10.1212\/WNL.0000000000004803","DOI":"10.1212\/WNL.0000000000004803"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Crespo-Burillo JA, Hernando-Quintana N, Ruiz-Palomino P, et al. Chorea secondary to striatal encephalitis due to anti-CV2\/CRMP5 antibodies. Case description and review of the literature. Neurologia. 2015;30(7):451-453. DOI: 10.1016\/j.nrleng.2013.10.025","DOI":"10.1016\/j.nrleng.2013.10.025"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Balint B, Vincent A, Meinck HM, Irani SR, Bathia KP. Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology. Brain. 2018;141(1):13-36. DOI: 10.1093\/brain\/awx189","DOI":"10.1093\/brain\/awx189"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev. 2017;97(2):839-887. DOI: 10.1152\/physrev.00010.2016","DOI":"10.1152\/physrev.00010.2016"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Dai X, Kuang L, Feng L, Yi X, Tang W, Liao Q, et al. Anti-dopamine receptor 2 antibody-positive encephalitis in adolescent. Front Neurol. 2020;11:471. DOI: 10.3389\/fneur.2020.00471","DOI":"10.3389\/fneur.2020.00471"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Hara M, Ari\u00f1o H, Petit-Pedrol M, Sabater L, Titulaer MJ, Mart\u00ednez-Hern\u00e1ndez E, et al. DPPX antibody-associated encephalitis. Neurology. 2017;88(14):1340-1348. DOI: 10.1212\/WNL.0000000000003796","DOI":"10.1212\/WNL.0000000000003796"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Spatola M, Sabater L, Planagum\u00e0 J, Mart\u00ednez-Hern\u00e1ndez E, Armangu\u00e9 T, Pr\u00fcss H, et al. Encephalitis with mGluR5 antibodies: Symptoms and antibody effects. Neurology. 2018;90(22):e1964-e1972. DOI: 10.1212\/WNL.0000000000005614","DOI":"10.1212\/WNL.0000000000005614"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Gaig C, Graus F, Compta Y, H\u00f6gl B, Bataller L, Br\u00fcggemann N, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017;88(18):1736-1743. DOI: 10.1212\/WNL.0000000000003887","DOI":"10.1212\/WNL.0000000000003887"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Najjar S, Steiner J, Najjar A, Bechter K. A clinical approach to new-onset psychosis associated with immune dysregulation: the concept of autoimmune psychosis. J Neuroinflammation. 2018;15(1):40. DOI: 10.1186\/s12974-018-1067-y","DOI":"10.1186\/s12974-018-1067-y"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391-404. DOI: 10.1016\/S1474-4422(15)00401-9","DOI":"10.1016\/S1474-4422(15)00401-9"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Jeannin-Mayer S, Andr\u00e9-Obadia N, Rosenberg S, Boutet C, Honnorat J, Antoine JC, et al. EEG analysis in anti-NMDA receptor encephalitis: description of typical patterns. Clin Neurophysiol. 2019;130(2):289-296. DOI: 10.1016\/j.clinph.2018.10.017","DOI":"10.1016\/j.clinph.2018.10.017"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Bayliss L, Restrepo-Mart\u00ednez M, Duarte A, Borja C, Espinola-Nadurille M. Are we missing subtle forms of anti-N-Methyl-D-Aspartate encephalitis with the current diagnostic approach? A case report. J Psychiatr Pract. 2019;25(5):383-390. DOI: 10.1097\/PRA.0000000000000412","DOI":"10.1097\/PRA.0000000000000412"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Probasco JC, Solnes L, Nalluri A, Cohen J, Jones KM, Zan E, et al. Decreased occipital lobe metabolism by FDG-PET\/CT. Neurol Neuroimmunol NeuroInflammation. 2017;5(1):1-9. DOI: 10.1212\/NXI.0000000000000413","DOI":"10.1212\/NXI.0000000000000413"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Kerik-Rotenberg N, Diaz-Meneses I, Hern\u00e1ndez-Ram\u00edrez R, Mu\u00f1oz-Casillas R, Reynoso-Mej\u00eda CA, Flores-Rivera J, et al. A metabolic brain pattern associated with Anti-N-Methyl-D-Aspartate receptor encephalitis. Psychosomatics. 2020;61(1):39-48. DOI: 10.1016\/j.psym.2019.08.007","DOI":"10.1016\/j.psym.2019.08.007"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Yuan J, Guan H, Zhou X, et al. Changing brain metabolism patterns in patients with ANMDARE serial 18F-FDG PET\/CT findings. Clin Nucl Med. 2016;41(5):366-370. DOI: 10.1097\/RLU.0000000000001164","DOI":"10.1097\/RLU.0000000000001164"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Gonz\u00e1lez-Valc\u00e1rcel J, Rosenfeld MR, Dalmau J. Differential diagnosis of encephalitis due to Anti-NMDA receptor antibodies. Neurologia. 2011;25(7):409-413. Disponible en: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3101880\/","DOI":"10.1016\/S2173-5808(10)70077-8"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Kuppuswamy PS, Takala CR, Sola CL. Management of psychiatric symptoms in anti-NMDAR encephalitis: A case series, literature review and future directions. Gen Hosp Psychiatry. 2014;36(4):388-391. DOI: 10.1016\/j.genhosppsych.2014.02.010","DOI":"10.1016\/j.genhosppsych.2014.02.010"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Warren N, O'Gorman C, McKeon G, Swayne A, Blum S, Siskind D. Psychiatric management of anti-NMDAR encephalitis: a cohort analysis. Psychol Med. 2021;51(3):435-440. DOI: 10.1017\/S0033291719003283","DOI":"10.1017\/S0033291719003283"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Lejuste F, Thomas L, Picard G, et al. Neuroleptic intolerance in patients with anti-NMDAR encephalitis. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e280. DOI: 10.1212\/NXI.0000000000000280","DOI":"10.1212\/NXI.0000000000000280"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Yamanaka D, Kawano T, Tateiwa H, Iwata H, Locatelli FM, Yokoyama M. Successful management of dexmedetomidine for postoperative intensive care sedation in a patient with anti-NMDA receptor encephalitis: a case report and animal experiment. Springerplus. 2016;5(1):1380. DOI: 10.1186\/s40064-016-3079-3","DOI":"10.1186\/s40064-016-3079-3"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Warren N, Grote V, O'Gorman C, Siskind D. Electroconvulsive therapy for anti-N-methyl-D-aspartate (NMDA) receptor encephalitis: a systematic review of cases. Brain Stimul. 2019;12(2):329-334. DOI: 10.1016\/j.brs.2018.11.016","DOI":"10.1016\/j.brs.2018.11.016"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J, et al. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol. 2013;70(9):1133-1139. DOI: 10.1001\/jamaneurol.2013.3216","DOI":"10.1001\/jamaneurol.2013.3216"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Broadley J, Seneviratne U, Beech P, Buzzard K, Butzkueven H, O'Brien T, et al. Prognosticating autoimmune encephalitis: a systematic review. J Autoimmun. 2019;96:24-34. DOI: 10.1016\/j.jaut.2018.10.014","DOI":"10.1016\/j.jaut.2018.10.014"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Titulaer MJ, McCracken L, Gabilondo I, Iizuka T, Kawachi I, Bataller L, et al. Late-onset anti-NMDA receptor encephalitis. Neurology. 2013;81(12):1058-1063. DOI: 10.1212\/WNL.0b013e3182a4a49c","DOI":"10.1212\/WNL.0b013e3182a4a49c"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Finke C, Kopp UA, Pr\u00fcss H, Dalmau J, Klaus-Peter W, Ploner CJ. Cognitive deficits following anti-NMDA receptor encephalitis. J Neurol Neurosurg Psychiatry. 2012;83(2):195-198. DOI: 10.1136\/jnnp-2011-300411","DOI":"10.1136\/jnnp-2011-300411"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Gibson LL, McKeever A, Coutinho E, Finke C, Pollak TA. Cognitive impact of neuronal antibodies: encephalitis and beyond. Transl Psychiatry. 2020;10(1):304. Disponible en: https:\/\/www.nature.com\/articles\/s41398-020-00989-x.pdf","DOI":"10.1038\/s41398-020-00989-x"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Witt JA, Helmstaedter C. Neuropsychological evaluations in limbic encephalitis. Brain Sci. 2021;11(5):576. DOI: 10.3390\/brainsci11050576","DOI":"10.3390\/brainsci11050576"}],"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/981\/1485","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/981\/1515","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/981\/1485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:17:40Z","timestamp":1744215460000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,7]]},"references-count":75,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,12,3]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v68i4.981","relation":{},"ISSN":["2448-9190","0002-5151"],"issn-type":[{"type":"electronic","value":"2448-9190"},{"type":"print","value":"0002-5151"}],"subject":[],"published":{"date-parts":[[2021,12,7]]}}}